Alumis (NASDAQ:ALMS – Get Free Report) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its rivals? We will compare Alumis to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings. Risk and Volatility Alumis […]